These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
84 related articles for article (PubMed ID: 12532427)
21. Pancreatic cancer: utility of dynamic contrast-enhanced MR imaging in assessment of antiangiogenic therapy. Akisik MF; Sandrasegaran K; Bu G; Lin C; Hutchins GD; Chiorean EG Radiology; 2010 Aug; 256(2):441-9. PubMed ID: 20515976 [TBL] [Abstract][Full Text] [Related]
22. Osteosarcoma: preliminary results of in vivo assessment of tumor necrosis after chemotherapy with diffusion- and perfusion-weighted magnetic resonance imaging. Uhl M; Saueressig U; van Buiren M; Kontny U; Niemeyer C; Köhler G; Ilyasov K; Langer M Invest Radiol; 2006 Aug; 41(8):618-23. PubMed ID: 16829744 [TBL] [Abstract][Full Text] [Related]
26. Dynamic contrast-enhanced MRI of prostate cancer at 3 T: a study of pharmacokinetic parameters. Ocak I; Bernardo M; Metzger G; Barrett T; Pinto P; Albert PS; Choyke PL AJR Am J Roentgenol; 2007 Oct; 189(4):849. PubMed ID: 17885055 [TBL] [Abstract][Full Text] [Related]
27. The temporal correlation of dynamic contrast-enhanced magnetic resonance imaging with tumor angiogenesis in a murine glioblastoma model. Veeravagu A; Hou LC; Hsu AR; Cai W; Greve JM; Chen X; Tse V Neurol Res; 2008 Nov; 30(9):952-9. PubMed ID: 18662497 [TBL] [Abstract][Full Text] [Related]
28. Magnetic resonance imaging of nude mice with heterotransplanted high-grade squamous cell carcinomas: use of a low-loaded, covalently bound Gd-Hsa conjugate as contrast agent with high tumor affinity. Kiessling F; Fink C; Hansen M; Bock M; Sinn H; Schrenk HH; Krix M; Egelhof T; Fusenig NE; Delorme S Invest Radiol; 2002 Apr; 37(4):193-8. PubMed ID: 11923641 [TBL] [Abstract][Full Text] [Related]
29. In-vivo longitudinal MRI study: an assessment of melanoma brain metastases in a clinically relevant mouse model. Henry MN; Chen Y; McFadden CD; Simedrea FC; Foster PJ Melanoma Res; 2015 Apr; 25(2):127-37. PubMed ID: 25513779 [TBL] [Abstract][Full Text] [Related]
30. Decrease in tumor apparent permeability-surface area product to a MRI macromolecular contrast medium following angiogenesis inhibition with correlations to cytotoxic drug accumulation. Daldrup-Link HE; Okuhata Y; Wolfe A; Srivastav S; Øie S; Ferrara N; Cohen RL; Shames DM; Brasch RC Microcirculation; 2004; 11(5):387-96. PubMed ID: 15280064 [TBL] [Abstract][Full Text] [Related]
31. Tumor microvascular changes in antiangiogenic treatment: assessment by magnetic resonance contrast media of different molecular weights. Turetschek K; Preda A; Novikov V; Brasch RC; Weinmann HJ; Wunderbaldinger P; Roberts TP J Magn Reson Imaging; 2004 Jul; 20(1):138-44. PubMed ID: 15221819 [TBL] [Abstract][Full Text] [Related]
32. Early effects of combretastatin A4 phosphate assessed by anatomic and carbogen-based functional magnetic resonance imaging on rat bladder tumors implanted in nude mice. Thomas CD; Walczak C; Kaffy J; Pontikis R; Jouanneau J; Volk A Neoplasia; 2006 Jul; 8(7):587-95. PubMed ID: 16867221 [TBL] [Abstract][Full Text] [Related]
33. [Folate-poly-L-lysine-Gd-DTPA as MR contrast agent for tumor imaging via folate receptor-targeted delivery]. Yuan Z; Liu SY; Xiao XS; Zhong GR; Jiang QJ Zhonghua Yi Xue Za Zhi; 2007 Mar; 87(10):673-8. PubMed ID: 17553304 [TBL] [Abstract][Full Text] [Related]
34. Intraindividual in vivo comparison of gadolinium contrast agents for pharmacokinetic analysis using dynamic contrast enhanced magnetic resonance imaging. Liang J; Sammet S; Yang X; Jia G; Takayama Y; Knopp MV Invest Radiol; 2010 May; 45(5):233-44. PubMed ID: 20351653 [TBL] [Abstract][Full Text] [Related]
35. Comparison of tumor blood perfusion assessed by dynamic contrast-enhanced MRI with tumor blood supply assessed by invasive imaging. Graff BA; Benjaminsen IC; Brurberg KG; Ruud EB; Rofstad EK J Magn Reson Imaging; 2005 Mar; 21(3):272-81. PubMed ID: 15723369 [TBL] [Abstract][Full Text] [Related]
36. Magnetic resonance imaging of thymic epithelial tumors. Kushihashi T; Fujisawa H; Munechika H Crit Rev Diagn Imaging; 1996 Aug; 37(3):191-259. PubMed ID: 8872410 [TBL] [Abstract][Full Text] [Related]
37. Assessment of tumor radioresponsiveness and metastatic potential by dynamic contrast-enhanced magnetic resonance imaging. Øvrebø KM; Gulliksrud K; Mathiesen B; Rofstad EK Int J Radiat Oncol Biol Phys; 2011 Sep; 81(1):255-61. PubMed ID: 21816291 [TBL] [Abstract][Full Text] [Related]
38. Magnetic resonance imaging of the pancreas and pancreatic tumors in a mouse orthotopic model of human cancer. Grimm J; Potthast A; Wunder A; Moore A Int J Cancer; 2003 Sep; 106(5):806-11. PubMed ID: 12866043 [TBL] [Abstract][Full Text] [Related]
39. Comparison of tumor histology to dynamic contrast enhanced magnetic resonance imaging-based physiological estimates. Aref M; Chaudhari AR; Bailey KL; Aref S; Wiener EC Magn Reson Imaging; 2008 Nov; 26(9):1279-93. PubMed ID: 18487033 [TBL] [Abstract][Full Text] [Related]
40. Heterogeneity in the angiogenic response of a BT474 human breast cancer to a novel vascular endothelial growth factor-receptor tyrosine kinase inhibitor: assessment by voxel analysis of dynamic contrast-enhanced MRI. Li KL; Wilmes LJ; Henry RG; Pallavicini MG; Park JW; Hu-Lowe DD; McShane TM; Shalinsky DR; Fu YJ; Brasch RC; Hylton NM J Magn Reson Imaging; 2005 Oct; 22(4):511-9. PubMed ID: 16161072 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]